论文部分内容阅读
目的 观察氧化苫参碱(oxymatrine,OM)预防及治疗大鼠肝纤维化的疗效并探讨其作用机制。方法 采用半乳糖胺诱导的大鼠肝纤维化模型,观察OM(90mg/kg)干预前后血及肝组织生物化学、羟脯氨酸含量、TGF β_1 mRNA表达水平及病理组织学改变。结果 OM干预组肝组织羟脯氨酸含量 (μg/mg)较模型组显著下降(预防观察组为0.50±0.11和0.99±0.14,t=8.366,P＜0.01;治疗观察组为0.44±0.04和0.70±0.06,t=9.839,P＜0.01);与模型组比较,干预组血清ALT、AST亦显著下降(P＜0.01);病理组织学显示干预组较模型组 Ⅰ、Ⅲ型胶原沉积减少,纤维间隔纤细,数量减少;干预织肝组织匀浆内超氧化物歧化酶活性(NU/mg)较模型组升高(预防观察组为149.81±15.28和95.22±16.33,t=7.309,P＜0.01;治疗观察组为157.68±19.54和119.88±14.94,t=4.348,P＜0.01), 而丙二醛(nmol/mg)低于模型组(预防观察组为2.06±0.17和4.57±0.37,t=17.529,P＜0.01;治疗观察组为1.76±0.24和3.10±0.17,t=12.697,P＜0.01);PT-PCR显示干预组TGF β_1 mRNA表达水平降低(预防观察组为0.21±0.01和0.50±0.01,t-48.665,P＜0.01;治疗观察组为0.18±0.02和0.38±0.01,t=22.464,P＜0.01)。结论 氧化苫参碱对半乳糖胺诱导的肝纤维化有预防及治疗作用,其部分机制为通过
Objective To observe the effect of oxymatrine (OM) on the prevention and treatment of hepatic fibrosis in rats and its mechanism. Methods The hepatic fibrosis model induced by galactosamine was used to observe the changes of biochemistry, hydroxyproline content, TGF β 1 mRNA expression and histopathological changes in blood and liver tissues before and after OM (90 mg / kg) intervention. Results The content of hydroxyproline (μg / mg) in liver tissue of OM intervention group was significantly lower than that of model group (0.50 ± 0.11 and 0.99 ± 0.14 in control group, t = 8.366, P <0.01) 0.70 ± 0.06, t = 9.839, P <0.01). Compared with the model group, serum ALT and AST in the intervention group also decreased significantly (P <0.01). Pathological histology showed that the deposition of type Ⅰ and Ⅲ collagen in the intervention group was decreased, The number of fibers was decreased and the number of fibers was decreased. The activity of superoxide dismutase (NU / mg) in the homogenate of liver tissue was higher than that of the untreated group (149.81 ± 15.28 and 95.22 ± 16.33, t = 7.309, P <0.01 ; The treatment observation group was 157.68 ± 19.54 and 119.88 ± 14.94, t = 4.348, P <0.01), while the MDA was lower than the model group (2.06 ± 0.17 and 4.57 ± 0.37 in the prevention group, t = 17.529, P <0.01; treatment observation group was 1.76 ± 0.24 and 3.10 ± 0.17, t = 12.697, P <0.01). PT-PCR showed that the expression of TGFβ_1 mRNA was decreased in the intervention group (0.21 ± 0.01 and 0.50 ± 0.01, t-48.665, P <0.01; treatment observation group was 0.18 ± 0.02 and 0.38 ± 0.01, t = 22.464, P <0.01). Conclusions Angstromine can prevent and treat hepatic fibrosis induced by galactosamine partly through